T2 Biosystems
T2 Biosystems Q2 Revenues More Than Double, Beat Estimates
The firm sold three T2Dx instruments in the quarter and saw an annualized run rate of sepsis tests of $98,000 per legacy instrument.
Cytovale Aiming to Enter Sepsis Testing Market With Rapid, Direct-From-Blood, Point-of-Care Platform
Premium
The company's core technology analyzes the mechanical properties of single cells and uses those properties to understand cell state and behavior.
The company is working to transition its instruments sold in the US from COVID-19 testing to sepsis testing and increase its installed base.
T2 Biosystems Q1 Revenues Nearly Triple
Product revenues were up 345 percent, as the firm increased US sepsis test utilization by 85 percent and sold four T2Dx instruments.
T2 Biosystems Q4 Revenues Jump 152 Percent on Strong Product Sales
The company said that it sold 57 T2Dx instruments in 2020, including 47 in the US, more than doubling its US installed base.
Nov 4, 2020
T2 Biosystems Q3 Revenues Triple, Beat Estimates
Sep 30, 2020
BARDA Exercises $10.5M Option on T2 Bio Contract
May 5, 2020
T2 Biosystems Q1 Revenues Jump 43 Percent
Apr 9, 2020
T2 Biosystems Receives Nasdaq Warning Letter
Feb 25, 2020
Oct 21, 2019